ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,708,597 | -44.3% | 510,094 | +0.0% | 0.00% | -50.0% |
| Q2 2023 | $4,859,151 | -12.9% | 509,879 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $5,577,846 | -35.1% | 508,019 | -12.5% | 0.00% | -42.9% |
| Q4 2022 | $8,597,157 | -22.8% | 580,889 | -0.4% | 0.01% | -30.0% |
| Q3 2022 | $11,140,000 | -7.4% | 582,936 | +3.2% | 0.01% | 0.0% |
| Q2 2022 | $12,032,000 | +19.1% | 564,644 | +7.6% | 0.01% | +42.9% |
| Q1 2022 | $10,103,000 | +0.0% | 524,559 | +7.7% | 0.01% | +16.7% |
| Q4 2021 | $10,102,000 | +12.4% | 487,071 | +29.5% | 0.01% | 0.0% |
| Q3 2021 | $8,985,000 | -12.6% | 376,074 | -0.1% | 0.01% | -14.3% |
| Q2 2021 | $10,278,000 | -5.5% | 376,620 | +0.2% | 0.01% | -12.5% |
| Q1 2021 | $10,872,000 | +34.1% | 375,796 | +30.3% | 0.01% | +33.3% |
| Q4 2020 | $8,110,000 | – | 288,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |